News

Fierce Pharma46m
Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal
AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...